Liu Hao, Guan Xinmiao, Lin Yuanyuan, Luo Minjing, Liang Changhao, Zhang Xinyue, Rong Hongguo, Fei Yutong
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Centre for Evidence-Based Chinese Medicine, Beijing GRADE Center, Beijing University of Chinese Medicine, Beijing, 100029, China.
BMC Complement Med Ther. 2025 Apr 3;25(1):125. doi: 10.1186/s12906-025-04864-4.
Cardiovascular diseases (CVD) represent a major global health challenge. Clinical research is increasingly leveraging patient perspectives to evaluate the efficacy of Traditional Chinese Medicine (TCM) in treating these conditions. This study reviews and summarizes the application and characteristics of Patient-reported outcomes (PROs) in TCM for CVD, the overarching goal is to provide a resource that can guide potential research directions for PROs endpoints in future TCM CVD clinical research.
We searched clinical studies of TCM for CVD from the World Health Organization International Clinical Trials Registry Platform registered between January 1, 2010, and February 22, 2025. The outcome types, whether PRO measures (PROMs) explicitly mentioned, study design, clinical study phases,age, gender, and geographic region were analyzed. We classified the studies that explicitly specified PROs into 15 categories based on the International Classification of Diseases-11 (ICD-11),and compared their PROMs with the Core Outcome Measures in Effectiveness Trials (COMET).
A total of 636 TCM CVD studies were included, of which 394 employed PROs. However, 103 studies did not specify the PROMs utilized, including 33 that involved TCM syndrome scores. None of the most frequently used PROMs were TCM-specific. The most frequently studied disease categories - chronic coronary heart diseases and heart failure - employed PROMs that were basically aligned with COMET recommendations. In contrast, other disease categories were not aligned with COMET.
In TCM clinical research on CVD, PROs have been commonly adopted as outcome measures, with usage steadily increasing. However, the application of TCM-specific PROMs remains limited, revealing a significant gap. PROMs recommended by COMET should be further investigated across a broader range of CVD categories. Furthermore, there is an urgent need for patient-centered research on TCM syndrome scores, highlighting the importance of developing robust, standardized TCM-specific PROMs tailored to this field.
心血管疾病(CVD)是全球主要的健康挑战。临床研究越来越多地利用患者的观点来评估中医(TCM)治疗这些疾病的疗效。本研究回顾并总结了中医治疗心血管疾病中患者报告结局(PROs)的应用及特点,总体目标是提供一种资源,以指导未来中医心血管疾病临床研究中PROs终点的潜在研究方向。
我们检索了2010年1月1日至2025年2月22日在世界卫生组织国际临床试验注册平台注册的中医治疗心血管疾病的临床研究。分析了结局类型、是否明确提及PRO测量(PROMs)、研究设计、临床研究阶段、年龄、性别和地理区域。我们根据国际疾病分类第11版(ICD-11)将明确指定PROs的研究分为15类,并将其PROMs与有效性试验的核心结局指标(COMET)进行比较。
共纳入636项中医心血管疾病研究,其中394项采用了PROs。然而,103项研究未明确所使用的PROMs,其中33项涉及中医证候评分。最常用的PROMs均非中医特有的。研究最多的疾病类别——慢性冠心病和心力衰竭——所采用的PROMs基本与COMET建议一致。相比之下,其他疾病类别与COMET不一致。
在中医心血管疾病临床研究中,PROs已被普遍用作结局指标,且使用量稳步增加。然而,中医特有的PROMs的应用仍然有限,存在显著差距。应在更广泛的心血管疾病类别中进一步研究COMET推荐的PROMs。此外,迫切需要开展以患者为中心的中医证候评分研究,突出开发适用于该领域的强大、标准化的中医特有的PROMs的重要性。